世界のホモ接合型家族性高コレステロール血症疫学市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4318
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、95ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、ホモ接合型家族性高コレステロール血症疫学の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（スタチン、MTP阻害剤（ロミタピド）、PCSK9阻害剤、その他）、用途別市場規模（病院、研究所、商業用、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・ホモ接合型家族性高コレステロール血症疫学の市場動向
・企業の競争状況、市場シェア
・ホモ接合型家族性高コレステロール血症疫学の種類別市場規模と予測2016-2027（スタチン、MTP阻害剤（ロミタピド）、PCSK9阻害剤、その他）
・ホモ接合型家族性高コレステロール血症疫学の用途別市場規模と予測2016-2027（病院、研究所、商業用、その他）
・ホモ接合型家族性高コレステロール血症疫学の北米市場規模2016-2027（アメリカ、カナダ）
・ホモ接合型家族性高コレステロール血症疫学の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・ホモ接合型家族性高コレステロール血症疫学のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・ホモ接合型家族性高コレステロール血症疫学の中南米市場規模2016-2027（メキシコ、ブラジル）
・ホモ接合型家族性高コレステロール血症疫学の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Regeneron Pharmaceuticals、Novartis、LIB Therapeutics、NeuroBo Pharmaceuticals、Arrowhead Pharmaceuticals、Amgen、Aegerion Pharmaceutical）
・結論

Market Analysis and Insights: Global Homozygous Familial Hypercholesterolemia Epidemiology Market
The global Homozygous Familial Hypercholesterolemia Epidemiology market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Homozygous Familial Hypercholesterolemia Epidemiology market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Homozygous Familial Hypercholesterolemia Epidemiology market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Homozygous Familial Hypercholesterolemia Epidemiology market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Homozygous Familial Hypercholesterolemia Epidemiology market.

Global Homozygous Familial Hypercholesterolemia Epidemiology Scope and Market Size
Homozygous Familial Hypercholesterolemia Epidemiology market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Homozygous Familial Hypercholesterolemia Epidemiology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Statins
MTP inhibitors (Lomitapide)
PCSK9 inhibitors
Other

Segment by Application
Hospital
Research Institute
Commercial
Other

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Regeneron Pharmaceuticals
Novartis
LIB Therapeutics
NeuroBo Pharmaceuticals
Arrowhead Pharmaceuticals
Amgen
Aegerion Pharmaceutical

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Statins
1.2.3 MTP inhibitors (Lomitapide)
1.2.4 PCSK9 inhibitors
1.2.5 Other
1.3 Market by Application
1.3.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Research Institute
1.3.4 Commercial
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Perspective (2016-2027)
2.2 Homozygous Familial Hypercholesterolemia Epidemiology Growth Trends by Regions
2.2.1 Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Homozygous Familial Hypercholesterolemia Epidemiology Historic Market Share by Regions (2016-2021)
2.2.3 Homozygous Familial Hypercholesterolemia Epidemiology Forecasted Market Size by Regions (2022-2027)
2.3 Homozygous Familial Hypercholesterolemia Epidemiology Industry Dynamic
2.3.1 Homozygous Familial Hypercholesterolemia Epidemiology Market Trends
2.3.2 Homozygous Familial Hypercholesterolemia Epidemiology Market Drivers
2.3.3 Homozygous Familial Hypercholesterolemia Epidemiology Market Challenges
2.3.4 Homozygous Familial Hypercholesterolemia Epidemiology Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Homozygous Familial Hypercholesterolemia Epidemiology Players by Revenue
3.1.1 Global Top Homozygous Familial Hypercholesterolemia Epidemiology Players by Revenue (2016-2021)
3.1.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share by Players (2016-2021)
3.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Homozygous Familial Hypercholesterolemia Epidemiology Revenue
3.4 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Concentration Ratio
3.4.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Homozygous Familial Hypercholesterolemia Epidemiology Revenue in 2020
3.5 Homozygous Familial Hypercholesterolemia Epidemiology Key Players Head office and Area Served
3.6 Key Players Homozygous Familial Hypercholesterolemia Epidemiology Product Solution and Service
3.7 Date of Enter into Homozygous Familial Hypercholesterolemia Epidemiology Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Homozygous Familial Hypercholesterolemia Epidemiology Breakdown Data by Type
4.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Historic Market Size by Type (2016-2021)
4.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Forecasted Market Size by Type (2022-2027)

5 Homozygous Familial Hypercholesterolemia Epidemiology Breakdown Data by Application
5.1 Global Homozygous Familial Hypercholesterolemia Epidemiology Historic Market Size by Application (2016-2021)
5.2 Global Homozygous Familial Hypercholesterolemia Epidemiology Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2016-2027)
6.2 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type
6.2.1 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021)
6.2.2 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027)
6.2.3 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2027)
6.3 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application
6.3.1 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021)
6.3.2 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027)
6.3.3 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2027)
6.4 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country
6.4.1 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2016-2021)
6.4.2 North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2016-2027)
7.2 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type
7.2.1 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021)
7.2.2 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027)
7.2.3 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2027)
7.3 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application
7.3.1 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021)
7.3.2 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027)
7.3.3 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2027)
7.4 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country
7.4.1 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2016-2021)
7.4.2 Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2016-2027)
8.2 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type
8.2.1 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2027)
8.3 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application
8.3.1 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2027)
8.4 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Region
8.4.1 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2016-2027)
9.2 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type
9.2.1 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021)
9.2.2 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027)
9.2.3 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2027)
9.3 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application
9.3.1 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021)
9.3.2 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027)
9.3.3 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2027)
9.4 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country
9.4.1 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2016-2021)
9.4.2 Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size (2016-2027)
10.2 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type
10.2.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2027)
10.3 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application
10.3.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2027)
10.4 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country
10.4.1 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Company Details
11.1.2 Regeneron Pharmaceuticals Business Overview
11.1.3 Regeneron Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Introduction
11.1.4 Regeneron Pharmaceuticals Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
11.1.5 Regeneron Pharmaceuticals Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Homozygous Familial Hypercholesterolemia Epidemiology Introduction
11.2.4 Novartis Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 LIB Therapeutics
11.3.1 LIB Therapeutics Company Details
11.3.2 LIB Therapeutics Business Overview
11.3.3 LIB Therapeutics Homozygous Familial Hypercholesterolemia Epidemiology Introduction
11.3.4 LIB Therapeutics Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
11.3.5 LIB Therapeutics Recent Development
11.4 NeuroBo Pharmaceuticals
11.4.1 NeuroBo Pharmaceuticals Company Details
11.4.2 NeuroBo Pharmaceuticals Business Overview
11.4.3 NeuroBo Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Introduction
11.4.4 NeuroBo Pharmaceuticals Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
11.4.5 NeuroBo Pharmaceuticals Recent Development
11.5 Arrowhead Pharmaceuticals
11.5.1 Arrowhead Pharmaceuticals Company Details
11.5.2 Arrowhead Pharmaceuticals Business Overview
11.5.3 Arrowhead Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Introduction
11.5.4 Arrowhead Pharmaceuticals Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
11.5.5 Arrowhead Pharmaceuticals Recent Development
11.6 Amgen
11.6.1 Amgen Company Details
11.6.2 Amgen Business Overview
11.6.3 Amgen Homozygous Familial Hypercholesterolemia Epidemiology Introduction
11.6.4 Amgen Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
11.6.5 Amgen Recent Development
11.7 Aegerion Pharmaceutical
11.7.1 Aegerion Pharmaceutical Company Details
11.7.2 Aegerion Pharmaceutical Business Overview
11.7.3 Aegerion Pharmaceutical Homozygous Familial Hypercholesterolemia Epidemiology Introduction
11.7.4 Aegerion Pharmaceutical Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
11.7.5 Aegerion Pharmaceutical Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Statins
Table 3. Key Players of MTP inhibitors (Lomitapide)
Table 4. Key Players of PCSK9 inhibitors
Table 5. Key Players of Other
Table 6. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Regions (2016-2021)
Table 10. Global Homozygous Familial Hypercholesterolemia Epidemiology Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Regions (2022-2027)
Table 12. Homozygous Familial Hypercholesterolemia Epidemiology Market Trends
Table 13. Homozygous Familial Hypercholesterolemia Epidemiology Market Drivers
Table 14. Homozygous Familial Hypercholesterolemia Epidemiology Market Challenges
Table 15. Homozygous Familial Hypercholesterolemia Epidemiology Market Restraints
Table 16. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Players (2016-2021)
Table 18. Global Top Homozygous Familial Hypercholesterolemia Epidemiology Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Homozygous Familial Hypercholesterolemia Epidemiology as of 2020)
Table 19. Ranking of Global Top Homozygous Familial Hypercholesterolemia Epidemiology Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Homozygous Familial Hypercholesterolemia Epidemiology Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Homozygous Familial Hypercholesterolemia Epidemiology Product Solution and Service
Table 23. Date of Enter into Homozygous Familial Hypercholesterolemia Epidemiology Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share by Type (2016-2021)
Table 27. Global Homozygous Familial Hypercholesterolemia Epidemiology Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share by Application (2016-2021)
Table 31. Global Homozygous Familial Hypercholesterolemia Epidemiology Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size by Country (2022-2027) & (US$ Million)
Table 63. Regeneron Pharmaceuticals Company Details
Table 64. Regeneron Pharmaceuticals Business Overview
Table 65. Regeneron Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Product
Table 66. Regeneron Pharmaceuticals Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021) & (US$ Million)
Table 67. Regeneron Pharmaceuticals Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Homozygous Familial Hypercholesterolemia Epidemiology Product
Table 71. Novartis Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. LIB Therapeutics Company Details
Table 74. LIB Therapeutics Business Overview
Table 75. LIB Therapeutics Homozygous Familial Hypercholesterolemia Epidemiology Product
Table 76. LIB Therapeutics Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021) & (US$ Million)
Table 77. LIB Therapeutics Recent Development
Table 78. NeuroBo Pharmaceuticals Company Details
Table 79. NeuroBo Pharmaceuticals Business Overview
Table 80. NeuroBo Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Product
Table 81. NeuroBo Pharmaceuticals Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021) & (US$ Million)
Table 82. NeuroBo Pharmaceuticals Recent Development
Table 83. Arrowhead Pharmaceuticals Company Details
Table 84. Arrowhead Pharmaceuticals Business Overview
Table 85. Arrowhead Pharmaceuticals Homozygous Familial Hypercholesterolemia Epidemiology Product
Table 86. Arrowhead Pharmaceuticals Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021) & (US$ Million)
Table 87. Arrowhead Pharmaceuticals Recent Development
Table 88. Amgen Company Details
Table 89. Amgen Business Overview
Table 90. Amgen Homozygous Familial Hypercholesterolemia Epidemiology Product
Table 91. Amgen Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021) & (US$ Million)
Table 92. Amgen Recent Development
Table 93. Aegerion Pharmaceutical Company Details
Table 94. Aegerion Pharmaceutical Business Overview
Table 95. Aegerion Pharmaceutical Homozygous Familial Hypercholesterolemia Epidemiology Product
Table 96. Aegerion Pharmaceutical Revenue in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021) & (US$ Million)
Table 97. Aegerion Pharmaceutical Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Type: 2020 VS 2027
Figure 2. Statins Features
Figure 3. MTP inhibitors (Lomitapide) Features
Figure 4. PCSK9 inhibitors Features
Figure 5. Other Features
Figure 6. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Research Institute Case Studies
Figure 9. Commercial Case Studies
Figure 10. Other Case Studies
Figure 11. Homozygous Familial Hypercholesterolemia Epidemiology Report Years Considered
Figure 12. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Regions: 2020 VS 2027
Figure 15. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Regions (2022-2027)
Figure 16. Global Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Players in 2020
Figure 17. Global Top Homozygous Familial Hypercholesterolemia Epidemiology Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Homozygous Familial Hypercholesterolemia Epidemiology as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Homozygous Familial Hypercholesterolemia Epidemiology Revenue in 2020
Figure 19. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share by Type (2016-2021)
Figure 20. Global Homozygous Familial Hypercholesterolemia Epidemiology Revenue Market Share by Type (2022-2027)
Figure 21. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Type (2016-2027)
Figure 23. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Application (2016-2027)
Figure 24. North America Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Country (2016-2027)
Figure 25. United States Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Type (2016-2027)
Figure 29. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Application (2016-2027)
Figure 30. Europe Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Country (2016-2027)
Figure 31. Germany Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Region (2016-2027)
Figure 41. China Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Type (2016-2027)
Figure 49. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Application (2016-2027)
Figure 50. Latin America Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Country (2016-2027)
Figure 51. Mexico Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Homozygous Familial Hypercholesterolemia Epidemiology Market Share by Country (2016-2027)
Figure 57. Turkey Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Homozygous Familial Hypercholesterolemia Epidemiology Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Regeneron Pharmaceuticals Revenue Growth Rate in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
Figure 61. Novartis Revenue Growth Rate in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
Figure 62. LIB Therapeutics Revenue Growth Rate in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
Figure 63. NeuroBo Pharmaceuticals Revenue Growth Rate in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
Figure 64. Arrowhead Pharmaceuticals Revenue Growth Rate in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
Figure 65. Amgen Revenue Growth Rate in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
Figure 66. Aegerion Pharmaceutical Revenue Growth Rate in Homozygous Familial Hypercholesterolemia Epidemiology Business (2016-2021)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed

以下、関連資料のご紹介

ヘテロ接合性家族性高コレステロール血症薬のグローバル市場調査 2019年

Global Heterozygous Familial Hypercholesterolemia Drug Market Professional Survey Report 2019
QYR9NV06000 2019年11月12日 109Pages
※本調査レポートは、ヘテロ接合性家族性高コレステロール血症薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、ゲムカベンカルシウム、MGL-3196、ST-10...

世界の家族性大腸腺腫症治療市場規模・現状・予測（2021年-2027年）

Global Familial Adenomatous Polyposis Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5736 2021年6月 89Pages
QYResearch社発行の本調査レポートでは、家族性大腸腺腫症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（イコサペント、塩酸エフロルニチン、アスピリン、CEQ-508、その他）、用途別市場規模（診療所、病院、その他）、主要地域別市場規模（...

世界の進行性家族性肝内胆汁うっ滞症2型治療市場規模・現状・予測（2021年-2027年）

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5963 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、進行性家族性肝内胆汁うっ滞症2型治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ウルソデオキシコール酸、コレスチラミン、リファンピシン、後期パイプライン薬、その他）、用途別市場規模（病院薬局、小売...

世界の気管支肺異形成症（BPD）疫学市場規模・現状・予測（2021年-2027年）

Global Bronchopulmonary Dysplasia (BPD) Epidemiology Market Size, Status and Forecast 2021-2027
QFJ1-3945 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、気管支肺異形成症（BPD）疫学の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ステロイド、界面活性剤、気管支拡張薬、ビタミンA、メチルキサンチン、利尿薬、抗生物質）、用途別市場規模（病院、薬局、研究所...

世界のメタボリックシンドローム市場規模・現状・予測（2021年-2027年）

Global Metabolic Syndrome Market Size, Status and Forecast 2021-2027
QFJ1-4493 2021年6月 120Pages
QYResearch社発行の本調査レポートでは、メタボリックシンドロームの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、ア...

世界の時差ボケ治療薬市場規模・現状・予測（2021年-2027年）

Global Jet Lag Therapy Pharmaceuticals Market Size, Status and Forecast 2021-2027
QFJ1-5816 2021年6月 98Pages
QYResearch社発行の本調査レポートでは、時差ボケ治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（Rx、OTC）、用途別市場規模（ビジネス旅行者、キャビンクルー、アスリート、季節旅行者、その他）、主要地域別市場規模（北米、アメリカ、欧州...

世界の海洋由来医薬品市場規模・現状・予測（2021年-2027年）

Global Marine-derived Pharmaceuticals Market Size, Status and Forecast 2021-2027
QFJ1-4462 2021年6月 100Pages
QYResearch社発行の本調査レポートでは、海洋由来医薬品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（フェノール、ステロイド、エーテル、ペプチド、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメ...

世界の女性健康用医薬品市場規模・現状・予測（2021年-2027年）

Global Pharmaceuticals for Women's Health Market Size, Status and Forecast 2021-2027
QFJ1-5946 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、女性健康用医薬品の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（顆粒、丸薬、粉末、チンキ剤、錠剤、カプセル、その他）、用途別市場規模（閉経後骨粗鬆症、子宮内膜症、多嚢胞性卵巣症候群、妊娠障害、その他）...

世界のポイントオブケア脂質検査市場規模・現状・予測（2021年-2027年）

Global Point of Care Lipid Test Market Size, Status and Forecast 2021-2027
QFJ1-4725 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、ポイントオブケア脂質検査の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（PoC脂質検査用機器、PoC脂質検査用消耗品）、用途別市場規模（高脂血症、高トリグリセリド血症、家族性高コレステロール血症、高リ...

世界の脂質パネルテスト市場規模・現状・予測（2021年-2027年）

Global Lipid Panel Test Market Size, Status and Forecast 2021-2027
QFJ1-4428 2021年6月 107Pages
QYResearch社発行の本調査レポートでは、脂質パネルテストの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（高脂血症、高トリグリセリド血症、家族性高コレステロール血症、高リポタンパク血症、タンジール病、その他）、用途別市場規模（家庭、診断研究所...

ヘテロ接合性家族性高コレステロール血症薬のグローバル市場調査 2019年 The global Heterozygous Familial Hypercholesterolemia Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Heterozygous Familial Hypercholesterolemia Drug volume and value at global level, regional …
世界の気管支肺異形成症（BPD）疫学市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Bronchopulmonary Dysplasia (BPD) Epidemiology Market The global Bronchopulmonary Dysplasia (BPD) Epidemiology market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy…
世界の家族性大腸腺腫症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Familial Adenomatous Polyposis Treatment Market The global Familial Adenomatous Polyposis Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analys…
世界の進行性家族性肝内胆汁うっ滞症2型治療市場規模・現状・予測（2021年-2027年） Progressive familial intrahepatic cholestasis (PFIC) type 2 is a rare genetic disorder that has no curative medication. Key players in the market only provide symptomatic treatment drugs. Market Analysis and Insights: Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market The g…
世界のBCL-2（B細胞リンパ腫2）阻害剤市場規模・現状・予測（2021年-2027年） Bcl-2 (B-cell lymphoma 2), encoded in humans by the BCL2 gene, is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inhibiting (anti-apoptotic) or inducing (pro-apoptotic) apoptosis. Market Analysis and Insights: Global BCL-2 (B-cell lympho…